The FDA label for Zepbound includes warnings to monitor patients for depression and suicidal thoughts or behaviors, though clinical trials have not established a definitive causal relationship
These 3.8 million Part D enrollees met the clinical criteria, did not have a diagnosis of type 2 diabetes, OSA, or MASH, or a GLP-1 Part D-covered prescription in 2023, and could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026
Is retatrutide available on the NHS in the UK
Tracking the weekly shot consistently is the simplest way to prevent it from happening again
Expedited appeals for urgent situations may be decided within 72 hours
Monitor blood glucose aggressively since GLP-1 agents impact glycemia and continue diabetes plans unless the surgeon or anesthesiologist dictates otherwise